SUMMARY Twenty-five patients with moderate essential hypertension (standing diastolic blood pressure 100-125 mmHg, phase 5) completed a single-blind placebo-controlled cross-over study comparing four week periods of treatment with atenolol 100 mg, metoprolol 100 mg, metoprolol durules 200 mg, slow-release oxprenolol 160 mg, and slow-release oxprenolol 320 mg respectively. All the drugs were significantly better than placebo at reducing resting blood pressure at 24 hours. Atenolol produced the greatest mean reduction of pressure and was the most effective drug for most patients, though the differences between atenolol and metoprolol durules were not statistically significant. These two drugs, however, were significantly more effective than the remainder. A similar ranking was seen with respect to the reduction of the blood pressure and heart rate response to exercise. None of the treatments had any significant effect on the patients' rating of perceived exertion during the exercise test.
In a chronic symptomless condition such as hypertension a once daily regimen with minimal side-effects is necessary to ensure good patient compliance. ' Several beta-blocking drugs can be given once daily to control high blood pressure.2 They differ not only in their ancillary pharmacological and physical properties, but also in their cost. We report here the results of a randomised cross-over study in hypertensive patients of once daily treatment with three commonly used beta-blocking drugs (atenolol, 'conventional' and slow-release metoprolol, slow-release oxprenolol) in doses considered by their manufacturers to be effective throughout 24 hours.
Patients and methods
Patients with recently diagnosed hypertension who were aged 60 years or less, who had a standing diastolic blood pressure of between 100 and 125 mmHg (phase 5) untreated for a minimum of eight weeks, who had no previous history of ischaemic heart disease or stroke, and who had no other concurrent medical problem or contraindication to beta-blockade, were considered for the study. Comprehensive investigations to exclude secondary causes of high blood pressure were not performed routinely, but all the potential trial patients had normal renal Received for publication 9 April 1981 function (no proteinuria, serum creatinine < 120 ,umol/l), and normal 24 hour urinary excretion of catecholamine metabolites on two occasions. None had grade 3 or 4 hypertensive retinal changes.
Patients fulfilling the above criteria were then seen every four weeks for the next 28 weeks in a special clinic. For the first four weeks they were given no treatment to ensure that their standing blood pressure remained above 100 mmHg, phase 5. They then received the trial drugs in random order according to a Latin square design. Each treatment period lasted four weeks and comprised once daily unmarked white tablets of atenolol 100 mg, metoprolol 100 mg, metoprolol durules 200 mg, slow release oxprenolol 160 mg, slow release oxprenolol 320 mg (2 x 160 mg tablets), or placebo taken in the morning. At the end of each period the patients returned to the clinic 24 hours after their last dose of tablets had been taken. Neither investigator knew the order of treatments for any patient.
At each visit to the trial clinic the resting electrocardiogram was recorded. The blood pressure and heart rate were measured after at least five minutes rest supine and after two minutes standing. Blood pressures were recorded in duplicate using a Hawksley random zero sphygmomanometer and the mean of each pair was calculated.
A continuous display of heart rate was then obtained from a single electrocardiographic chest lead and the patients stood on a treadmill until the heart rate had stabilised. They were then exercised according to the standard Bruce protocol for either three or four three minute periods of progressive exercise (the duration of exercise having been determined for each patient at the end of the run-in no-treatment period). During the last 30 seconds of each exercise period the patients indicated on the Borg 15 
Results
Twenty-six patients were entered in the study after the run-in four week period. One man was subsequently withdrawn after experiencing a transient ischaemic episode during exercise at home, but the remaining 25 patients completed the six treatment periods.
There were 22 men and three women, mean age 47 years (range 30 to 60 years), and mean duration of known hypertension three months (range 1 to 12 months). Five patients had received hypotensive treatment before referral to the clinic (diuretics (three), beta-blockers (two)). Of the 25 patients, 20 agreed to the regular exercise test; in the others only resting, standing, and supine blood pressures were measured.
RESTING BLOOD PRESSURE Table 1 shows the mean resting blood pressure and heart rate at the end of each randomised period. All the active treatments were significantly better than the placebo at reducing blood pressure (p<001 at least). Atenolol had a significantly better hypotensive effect than all the other treatments (p<0005 at least), except for metoprolol durules, where only the difference in standing diastolic pressure was significant (p<002). Metoprolol durules were significantly better than metoprolol, slow-release oxprenolol 160 mg, and slow-release oxprenolol 320 mg for diastolic pressure (p<001 at least). There were no significant differences in the effect on blood pressure of metoprolol, and slow-release oxprenolol 160 mg or 320 mg. Table 2 shows the degree of reduction of resting diastolic blood pressure caused by the various treatments in comparison with placebo. Table 2 also shows the number of patients who had their standing diastolic blood pressure reduced to less than 95 mmHg.
EXERCISE BLOOD PRESSURE AND HEART RATE
Of the 20 patients who undertook the exercise tests, 17 always completed the fourth level of exercise (12 minutes) and three patients always completed the third level (9 minutes). Table 3 shows the mean (±SEM) values for pre-exercise and exercise systolic blood pressure and heart rate. The same ranking of the treatments was apparent as in the analysis of the resting results. There was no significant difference between atenolol and metoprolol durules; these two drugs significantly reduced both heart rate and blood pressure compared with placebo (p<0-001). The percentage reduction in blood pressure at each exercise level produced by atenolol and metoprolol durules was, however, modest, varying between 9 and 12%. Similarly the percentage reduction in heart rate Discussion compared with placebo varied by 14 to 20%. There were no consistently significant differences between We have confirmed that all the drugs used in this the effects of the other three treatments on blood study have a significant hypotensive effect 24 hours pressure and heart rate during exercise compared with after the last dose has been taken, though they differ placebo. significantly in the degree of blood pressure reduction The Figure illustrates these results graphically they produce at this point both at rest, and during using the regression lines from the treatment means exercise. These differences may be the result in part for clarity. The figure shows that some degree of of the doses selected for study and of the particular beta-blockade persists at 24 hours for all the treat-formulation of the drug(s). ments and that the degree of beta-blockade does not A slow release formulation of a drug with a short change as the severity of the exercise is increased. plasma half-life is an attempt to prolong plasma levels Table 4 shows the mean (+ range) Borg rating for and pharmacological effects to the extent that the perceived exertion during the exercise tests. There drug need be given less frequently. Though the were no significant differences in rating between any slow-release formulation of oxprenolol has been of the treatments and the placebo despite obvious shown to have some advantages over conventional differences in heart rate and systolic blood pressure oxprenolol,4 5 when compared with other betaproduced by some of the drugs.
blockers over the whole 24 hours in fixed dose studies, 156±5  159±4  163±4  165±4  163±5  3 min  182±4  161±4  167±4  170±6  175±5  173±5  6 min  194±5  169±5  174±5  184±6  183±5  183±6  9 min  208±5  182±5  188±6  197±6  196±6  208±5  12 min  221±4  198±5  203±8  207±7  208±5  221±4  Final exercise level  221±4  195±5  201±7  209±7  210±5  221±4   Post-exercise  1 niin  200±3  181±4  183±6  191±5  196±5  200±3  3 min  179±4  155±4  163±5  170±5  173±4  170±4 Heart rate/min Pre-exercise  83±2  69±2  71±2  76±2  81±2  75±2  3 min  98±2  82±2  85±2  93±3  95±2  91±2  6 min  111±2  96±2  99±3  108±3  107±2  103±2  9 min  132±3  115±2  118±3  127±3  126±3  123±3  12 min  154±4  134±4  138±4  150±4  148±4  145±3  Final exercise level  151±4  131±4  136±4  148±3  146±4  143±3  Post-exercise  1 min  128±4  105±4  110±5  123±4  122±4  115±3  3 min  108±3  89±3  93±4  104±3  105±4  98±3 group its effectiveness has been questioned.6 7 Our results confirm the disappointing hypotensive effect of slowrelease oxprenolol in comparison with other drugs given once daily, and further suggest that a doubling of the morning dose confers no added benefit. Metoprolol also has a relatively short elimination half-life which, though it may increase slightly with chronic treatment, remains much less than that of atenolol.8 9 A slow-release formulation containing 200 mg metoprolol given once daily has been shown to be approximately equivalent to the conventional formulation in a dose of 100 mg given twice daily.'0 What has been more controversial, however, is the relative hypotensive potency of once daily metoprolol 100 mg and atenolol 100 mg at 24 hours."-3 Of those claiming equivalence the study by Comerford and Besterman is the most persuasive, though not for exercise tachycardia, even at the low levels of exercise used in their study.14 The data presented from our study, however, do not confirm their results for conventional metoprolol, but do indicate that the slow-release formulation represents a significant improvement, being in most instances insignificantly different from atenolol with regard to both heart rate and resting and exercise blood pressure.
The clinical relevance of reducing the blood pressure and heart rate response to exercise is not clear. Whereas a hypotensive effect at rest can be maintained throughout a 24 hour period with a number of beta-blocking drugs given once daily the degree of reduction of these responses to exercise diminishes. In this study the two most effective drugs, atenolol and metoprolol durules, produced no more than a 9 to 12% reduction in exercise systolic pressure, and a 14 to 20% reduction in exercise heart rate compared with placebo at 24 hours.
These modest reductions in systolic pressure and heart rate, however, were not reflected in the patients' own subjective assessment of the effort involved during the exercise tests. Though single oral doses of either a cardioselective or non-selective beta-blocker have been shown to increase the perceived exertion score during exercise,15 our results clearly show that when given chronically (four weeks) this is not the case. Neither did we observe any change in the ability of our patients to complete at each visit the degree of exercise determined before randomisation to the various treatments. These differences between the acute and chronic effects of beta-blockade presumably 
